BerGenBio ASA: Share capital increase registered

Bergen 29 June 2023: Reference is made to previous stock exchange announcements from BerGenBio ASA ("BerGenBio" or the "Company") regarding the partially underwritten rights issue of up to 2,500,000,000 new shares (the "Offer Shares") in the Company, raising gross proceeds of up to NOK 250 million (the "Rights Issue"). Reference is further made to the stock exchange notice published on 27 June 2023 regarding a resolution to increase the share capital for settlement of parts of the underwriting commission through the issuance of 31,872,000 new shares (the "Fee Shares") to certain underwriters of the Rights Issue.

The share capital increases relating to the issuance of the Fee Shares have now been registered with the Norwegian Register of Business Enterprises. The share capital has been increased with NOK 3,187,200 through the issuance of 31,872,000 new shares.

The new share capital is NOK 262,053,253.20 divided into 2,620,532,532 shares, each with a par value of NOK 0.10.

The Fee Shares are expected to be delivered to the underwriters on or about 30 June 2023.

For further information, please contact:


Martin Olin CEO, BerGenBio ASA


Rune Skeie, CFO, BerGenBio ASA


About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.


The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit


This information is published in accordance with the requirements of the Oslo Rule Book II and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.